OSENVELT

GrowthmAb

denosumab-bmwo

BLAINJECTIONINJECTABLE

Approved

Feb 2025

Lifecycle

Growth

Competitive Pressure

30/100

Mechanism of Action

RANK Ligand Blocking Activity

Pharmacologic Class:

RANK Ligand Inhibitor

Company

Korea - Incheon

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers